Kiora Pharmaceuticals (KPRX) Consolidated Net Income (2016 - 2026)

Kiora Pharmaceuticals (KPRX) has reported Consolidated Net Income for 11 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Consolidated Net Income rose 3.41% year-over-year to -$2.1 million; the trailing twelve-month figure through Jun 2026 stood at -$11.0 million (up 44.19% YoY), and the FY2025 full-year result was -$10.8 million, down 251.2% from the prior year.
• Consolidated Net Income advanced to -$2.1 million in Q2 2026 per KPRX's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $13.5 million in Q1 2024 and bottomed at -$12.2 million in Q3 2023.
• Historically, Consolidated Net Income has averaged -$3.4 million across 5 years, with a median of -$2.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Consolidated Net Income slumped 190.73% in 2022, then surged 801.91% in 2024.
• Over 5 years, Consolidated Net Income stood at -$5.1 million in 2022, then gained by 15.48% to -$4.3 million in 2023, then slumped by 95.36% to -$8.5 million in 2024, then gained by 23.38% to -$6.5 million in 2025, then surged by 68.01% to -$2.1 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$2.1 million, -$2.4 million, and -$6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.